Abel, Mary Kathryn
Shui, Amy M.
Chien, A. Jo
Rugo, Hope S.
Melisko, Michelle
Baehner, Frederick
Mukhtar, Rita A.
Funding for this research was provided by:
National Cancer Institute (K08CA256047)
Article History
Received: 4 April 2022
Accepted: 8 June 2022
First Online: 9 July 2022
Disclosure
: A. Jo Chien receives research funding from Merck, Puma, Amgen, and Seattle Genetics. Hope S. Rugo receives research support for clinical trials through the University of California from Pfizer, Merck, Novartis, Lilly, Roche, Odonate, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Astra Zeneca, OBI, Gilead, and Ayala, and has also received honoraria from Puma, Samsung, and Napo. Michelle Melisko receives research funding from Astra Zeneca, Novartis, KCRN Research, and Puma, and consulting fees from Biotheranostics. Frederick Baehner is the Chief Medical Officer of Precision Oncology at Exact Sciences. Mary Kathryn Abel, Amy M. Shui, and Rita A. Mukhtar declare no competing interests.
: Our study was deemed exempt by the University of California San Francisco Institutional Review Board.